BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1779-1786. [PMID: 21875430 DOI: 10.1111/j.1440-1746.2011.06891.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhao X, Voutila J, Ghobrial S, Habib NA, Reebye V. Treatment of Liver Cancer by C/EBPA saRNA. Adv Exp Med Biol 2017;983:189-94. [PMID: 28639200 DOI: 10.1007/978-981-10-4310-9_13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. DEB-TACE: a standard review. Future Oncol. 2018;14:2969-2984. [PMID: 29987957 DOI: 10.2217/fon-2018-0136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
3 Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, Barile A, Del Sole A, Masciocchi C, Lucignani G, Carrafiello G. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1021-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
4 Li J, Wu DD, Zhang JX, Wang J, Ma JJ, Hu X, Dong WG. Mitochondrial pathway mediated by reactive oxygen species involvement in α-hederin-induced apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2018; 24(17): 1901-1910 [PMID: 29740205 DOI: 10.3748/wjg.v24.i17.1901] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
5 Asghar K, Farooq A, Zulfiqar B, Rashid MU. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2286-2293 [PMID: 28428708 DOI: 10.3748/wjg.v23.i13.2286] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
6 Holvoet T, Raevens S, Vandewynckel YP, Van Biesen W, Geboes K, Van Vlierberghe H. Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Dig Liver Dis. 2015;47:877-883. [PMID: 26250948 DOI: 10.1016/j.dld.2015.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
7 Long S, Peng F, Song B, Wang L, Chen J, Shang B. Heat Shock Protein Beta 1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Int J Gen Med 2021;14:5483-92. [PMID: 34531676 DOI: 10.2147/IJGM.S330608] [Reference Citation Analysis]
8 Ding Q, Xia Y, Ding S, Lu P, Sun L, Fan Y, Li X, Wang Y, Tian DA, Liu M. Potential role of CXCL9 induced by endothelial cells/CD133+ liver cancer cells co-culture system in tumor transendothelial migration. Genes Cancer 2016;7:254-9. [PMID: 27738495 DOI: 10.18632/genesandcancer.116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
9 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
10 Bridges JF, Joy SM, Blauvelt BM, Yan W, Marsteller JA. An international comparison of stakeholder motivation to implement liver cancer control. Health Policy Plan 2015;30:645-55. [PMID: 24974105 DOI: 10.1093/heapol/czu044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
12 Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, He DX, Tang SS, Wei H, Yu CY. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2019;11:10578-88. [PMID: 30802029 DOI: 10.1021/acsami.9b00634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
13 Tang S, Xu B, Li J, Zhong M, Hong Z, Zhao W, Zeng T, He X. Ozone induces BEL7402 cell apoptosis by increasing reactive oxygen species production and activating JNK. Ann Transl Med 2021;9:1257. [PMID: 34532394 DOI: 10.21037/atm-21-3233] [Reference Citation Analysis]
14 Boyle DA. Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses. Asia Pac J Oncol Nurs 2017;4:98-103. [PMID: 28503639 DOI: 10.4103/2347-5625.204497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Joy SM, Blauvelt BM, Tuncer MA, Beaugrand M, Sangro B, Colombo M, Bridges JF. Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. Eur J Public Health 2013;23:951-7. [PMID: 23531524 DOI: 10.1093/eurpub/cks173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
17 Xu X, Liu C, Qu K, Song Y, Zhang P, Zhang Y. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2014;13:234-41. [DOI: 10.1016/s1499-3872(14)60037-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cahalane AM, Purcell YM, Lavelle LP, McEvoy SH, Ryan ER, O'Toole E, Malone DE. Which is the best current guideline for the diagnosis and management of cystic pancreatic neoplasms? An appraisal using evidence-based practice methods. Eur Radiol 2016;26:3121-8. [PMID: 26762943 DOI: 10.1007/s00330-015-4160-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, Chen Q, Ma C, Zhu W, Li J, Li N. An appraisal of clinical practice guidelines for constipation: a right attitude towards to guidelines. BMC Gastroenterol 2016;16:52. [PMID: 27142422 DOI: 10.1186/s12876-016-0466-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Wang Y, Luo Q, Li Y, Wang H, Deng S, Wei S, Li X. Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. PLoS One. 2014;9:e103939. [PMID: 25105961 DOI: 10.1371/journal.pone.0103939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]